Samsung Bioepis Eyes US Trastuzumab Potential As It Hits Profitability
Firm Recently Entered Crowded US Trastuzumab Market With Ontruzant
Incheon-based Samsung Bioepis believes there is a 'good opportunity' in the US trastuzumab market • Source: Shutterstock 
